dr. sonpavde discusses a study of fixed-dose durvalumab and tremelimumab in urothelial carcinoma
Published 6 years ago • 178 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
1:05
dr. sonpavde on the role of durvalumab in platinum-refractory bladder cancer
-
1:27
dr. sonpavde on enfortumab vedotin data in bladder cancer
-
0:50
dr. sonpavde on immunotherapy combination studies in urothelial carcinoma
-
1:25
dr. sonpavde on the next steps for atezolizumab in urothelial carcinoma
-
1:10
dr. powles discusses the future of durvalumab in bladder cancer
-
1:07
dr. balar on impact of durvalumab plus tremelimumab in bladder cancer
-
1:08
dr. rafii on durvaluamb in patients with urothelial bladder cancer
-
1:33
dr. balar on results of durvalumab plus tremelimumab in bladder cancer
-
1:47
dr. sonpavde on the safety profile of erdafitinib in bladder cancer
-
1:58
dr. sonpavde on combining vegf/pd-1 inhibitors in metastatic urothelial carcinoma
-
2:36
dr. joshi discusses durvalumab and radiation therapy in bladder cancer
-
1:26
dr. sonpavde on remaining questions with immunotherapy in bladder cancer
-
2:03
durvalumab fda approval for bladder cancer
-
1:24
dr. sonpavde on neoadjuvant immunotherapy in bladder cancer
-
2:55
highlights of durvalumab for advanced bladder cancer
-
8:18
asco gu 2020: dr. sonpavde highlights advancements in bladder cancer
-
1:05
dr. sonpavde on the biggest challenges in bladder cancer
-
2:07
dr. sonpavde on emerging immunotherapy approaches in bladder cancer
-
3:19
fda approval of durvalumab for advanced bladder cancer